A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: Preliminary results

Neurological Sciences

Volumn 26, Issue SUPPL. 4, 2005, Pages

  Milanese, C ^a   Beghi, E ^b   Giordano, L ^b   La Mantia, L ^a   Mascoli, N ^a   Confalonieri, P ^a   Baldini, D ^c   Bergamaschi, R ^d   Bianchi, G ^e   Cavaletti, G ^f   Clerici, R ^g   Cordioli, C ^h   Ferrari, E ⁱ   Gambaro, P ^j   Ghezzi, A ^k   Lo Russo, L ^l   Martinelli, V ^m   Palumbo, R ⁿ   Perrone, P ^o   Previdi, P ^p   Protti, A ^q   Rezzonico, M ^r   Robotti, M ^s   Rottoli, M R ^t   Scarpini, E ^u   more..

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c O Sondrio   (Italy)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e O Manzoni   (Italy)

^f Department of Dermatology   (Italy)

^g O Valduce   (Italy)

^h O Civile   (Italy)

ⁱ O Cremona   (Italy)

^j II Div Mal Infettive   (Italy)

^k Centro SM   (Italy)

^l O Chiari ^*  (Italy)

^m Neurological Unit   (Italy)

ⁿ Maggiore Hospital   (Italy)

^o Legnano Hospital   (Italy)

^p CARLO POMA HOSPITAL   (Italy)

^q O Niguarda   (Italy)

^r SANT ANNA HOSPITAL   (Italy)

^s Policlinico Universitario   (Italy)

^t Riuniti Hospital   (Italy)

^u University Hospital Policlinico   (Italy)

more..

Author keywords

Copolymer 1; Interferons; Relapsing remitting multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; MITOXANTRONE;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; ITALY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PHYSICAL DISABILITY; POSTMARKETING SURVEILLANCE; RELAPSE; REMISSION; SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; ITALY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PRODUCT SURVEILLANCE, POSTMARKETING; RECURRENCE; TREATMENT OUTCOME;

EID: 30644457439     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-005-0509-3     Document Type: Article

References (5)

1. The IFNB Multiple Sclerosis Study Group and the University of British Columbia. MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45:1277-1285
2. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 43:655-651
3. PRIMS study group (1998) Randomised double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 352:1498-1504
4. Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276
5. Milanese C, La Mantia L, Palumbo R et al (2003) A postmarketing study on interferon beta 1b and 1a treatment in relapsing remitting multiple sclerosis: Different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 74:1689-1692